Australia markets closed
  • ALL ORDS

    7,552.10
    -40.60 (-0.53%)
     
  • AUD/USD

    0.7583
    +0.0030 (+0.39%)
     
  • ASX 200

    7,298.50
    -43.70 (-0.60%)
     
  • OIL

    73.41
    +0.56 (+0.77%)
     
  • GOLD

    1,783.90
    +6.50 (+0.37%)
     
  • BTC-AUD

    44,930.54
    +2,909.11 (+6.92%)
     
  • CMC Crypto 200

    813.96
    +19.63 (+2.47%)
     

Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

FLORHAM PARK, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Bank of America Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021 at 8:45 a.m. ET.

Company management will also participate in one-on-one meetings during the virtual conference.

To access the live webcast and archived recording of the presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recording will be available for 90 days following the event.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at www.phathompharma.com or follow the Company on follow the Company on social media: LinkedIn at www.linkedin.com/company/phathompharma and Twitter @PhathomPharma.

CONTACTS
Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com

Investor Contact:
Todd Branning
1-877-742-8466
ir@phathompharma.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting